La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Syndax Pharmaceuticals Croissance future
Future contrôle des critères 2/6
Syndax Pharmaceuticals is forecast to grow earnings and revenue by 30.6% and 52.4% per annum respectively. EPS is expected to grow by 34.4% per annum. Return on equity is forecast to be -61.2% in 3 years.
Informations clés
30.6%
Taux de croissance des bénéfices
34.4%
Taux de croissance du BPA
Biotechs croissance des bénéfices | 30.4% |
Taux de croissance des recettes | 52.4% |
Rendement futur des capitaux propres | -61.2% |
Couverture par les analystes | Good |
Dernière mise à jour | 15 Aug 2024 |
Mises à jour récentes de la croissance future
Recent updates
Syndax: Gearing Up For Launches
Jun 21Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Jun 20Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope
Mar 28Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation
Mar 04Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?
Nov 20Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth
Sep 27Syndax Pharmaceuticals Q2 2022 Earnings Preview
Aug 07Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs
Apr 08Prévisions de croissance des bénéfices et des revenus
Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
---|---|---|---|---|---|
12/31/2026 | 230 | -210 | -95 | -148 | 11 |
12/31/2025 | 103 | -297 | -175 | -240 | 12 |
12/31/2024 | 32 | -318 | -290 | -263 | 12 |
6/30/2024 | 4 | -264 | -241 | -241 | N/A |
3/31/2024 | N/A | -241 | -205 | -205 | N/A |
12/31/2023 | N/A | -209 | -161 | -161 | N/A |
9/30/2023 | N/A | -176 | -142 | -142 | N/A |
6/30/2023 | N/A | -160 | -126 | -126 | N/A |
3/31/2023 | N/A | -153 | -131 | -131 | N/A |
12/31/2022 | N/A | -149 | -134 | -134 | N/A |
9/30/2022 | 127 | -14 | -10 | -10 | N/A |
6/30/2022 | 139 | 1 | -7 | -6 | N/A |
3/31/2022 | 139 | 15 | 10 | 10 | N/A |
12/31/2021 | 140 | 25 | 29 | 29 | N/A |
9/30/2021 | 14 | -92 | -87 | -87 | N/A |
6/30/2021 | 2 | -91 | -81 | -81 | N/A |
3/31/2021 | 2 | -86 | -78 | -78 | N/A |
12/31/2020 | 2 | -77 | -71 | -71 | N/A |
9/30/2020 | 2 | -71 | -68 | -68 | N/A |
6/30/2020 | 2 | -63 | -59 | -59 | N/A |
3/31/2020 | 2 | -61 | -50 | -50 | N/A |
12/31/2019 | 2 | -56 | -51 | -51 | N/A |
9/30/2019 | 2 | -61 | -53 | -53 | N/A |
6/30/2019 | 2 | -65 | -63 | -63 | N/A |
3/31/2019 | 2 | -69 | -66 | -65 | N/A |
12/31/2018 | 2 | -74 | -69 | -69 | N/A |
9/30/2018 | 2 | -74 | -66 | -66 | N/A |
6/30/2018 | 2 | -72 | -58 | -58 | N/A |
3/31/2018 | 2 | -67 | N/A | -55 | N/A |
12/31/2017 | 2 | -61 | N/A | -47 | N/A |
9/30/2017 | 1 | -53 | N/A | -45 | N/A |
6/30/2017 | 1 | -52 | N/A | -46 | N/A |
3/31/2017 | 1 | -47 | N/A | -41 | N/A |
12/31/2016 | 1 | -47 | N/A | -35 | N/A |
9/30/2016 | 1 | -45 | N/A | -29 | N/A |
6/30/2016 | 1 | -87 | N/A | -23 | N/A |
3/31/2016 | 1 | -105 | N/A | -20 | N/A |
12/31/2015 | 1 | -104 | N/A | -2 | N/A |
9/30/2015 | 0 | -100 | N/A | -2 | N/A |
6/30/2015 | 0 | -53 | N/A | 1 | N/A |
3/31/2015 | N/A | -33 | N/A | 1 | N/A |
12/31/2014 | N/A | -26 | N/A | -14 | N/A |
9/30/2014 | N/A | -31 | N/A | -14 | N/A |
6/30/2014 | N/A | -72 | N/A | -13 | N/A |
3/31/2014 | N/A | -67 | N/A | -10 | N/A |
12/31/2013 | N/A | -60 | N/A | -7 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: SNDX is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: SNDX is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: SNDX is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: SNDX's revenue (52.4% per year) is forecast to grow faster than the US market (8.8% per year).
Croissance élevée des revenus: SNDX's revenue (52.4% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: SNDX is forecast to be unprofitable in 3 years.